New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis
Carmona Rocha, Elena (Institut de Recerca Sant Pau)
Rusiñol, Lluís (Institut de Recerca Sant Pau)
Puig Sanz, Lluís (Institut de Recerca Sant Pau)
Universitat Autònoma de Barcelona. Departament de Medicina

Date:	2024
Abstract:	The introduction of biologic therapies has led to dramatic improvements in the management of moderate-to-severe psoriasis. Even though the efficacy and safety of the newer biologic agents are difficult to match, oral administration is considered an important advantage by many patients. Current research is focused on the development of oral therapies with improved efficacy and safety compared with available alternatives, as exemplified by deucravacitinib, the first oral allosteric Tyk2 inhibitor approved for the treatment of moderate to severe psoriasis in adults. Recent advances in our knowledge of psoriasis pathogenesis have also led to the development of targeted topical molecules, mostly focused on intracellular signaling pathways such as AhR, PDE-4, and Jak-STAT. Tapinarof (an AhR modulator) and roflumilast (a PDE-4 inhibitor) have exhibited favorable efficacy and safety outcomes and have been approved by the FDA for the topical treatment of plaque psoriasis. This revision focuses on the most recent oral and topical therapies available for psoriasis, especially those that are currently under evaluation and development for the treatment of psoriasis.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Psoriasis ; Oral therapies ; Topical therapies ; Biologics ; Jak inhibitors ; PDE4 inhibitors ; Systemic treatment ; IL-17 inhibitors ; IL-23 inhibitors ; Tapinarof ; Roflumilast
Published in:	Pharmaceutics, Vol. 16, Num. 2 (february 2024) , ISSN 1999-4923

DOI: 10.3390/pharmaceutics16020239
PMID: 38399292

36 p, 1.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles